OTCMKTS:EPGNY

Epigenomics Competitors

$12.39
-1.38 (-10.02 %)
(As of 04/16/2021 08:10 PM ET)
Add
Compare
Today's Range
$12.39
Now: $12.39
$12.39
50-Day Range
$13.60
MA: $13.88
$16.05
52-Week Range
$12.39
Now: $12.39
$159.16
Volume200 shs
Average Volume173 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Epigenomics (OTCMKTS:EPGNY) Vs. OLK, OCDX, BDSX, LHDX, NOTV, and AKU

Should you be buying EPGNY stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to Epigenomics, including Olink Holding AB (publ) (OLK), Ortho Clinical Diagnostics (OCDX), Biodesix (BDSX), Lucira Health (LHDX), Inotiv (NOTV), and Akumin (AKU).

Olink Holding AB (publ) (NASDAQ:OLK) and Epigenomics (OTCMKTS:EPGNY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Olink Holding AB (publ) and Epigenomics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Olink Holding AB (publ)0000N/A
Epigenomics0000N/A

Earnings & Valuation

This table compares Olink Holding AB (publ) and Epigenomics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Olink Holding AB (publ)N/AN/AN/AN/AN/A
EpigenomicsN/AN/AN/AN/AN/A

Profitability

This table compares Olink Holding AB (publ) and Epigenomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Olink Holding AB (publ)N/AN/AN/A
EpigenomicsN/AN/AN/A

Epigenomics (OTCMKTS:EPGNY) and Ortho Clinical Diagnostics (NASDAQ:OCDX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Profitability

This table compares Epigenomics and Ortho Clinical Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EpigenomicsN/AN/AN/A
Ortho Clinical DiagnosticsN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and target prices for Epigenomics and Ortho Clinical Diagnostics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Epigenomics0000N/A
Ortho Clinical Diagnostics011102.92

Ortho Clinical Diagnostics has a consensus price target of $24.2727, suggesting a potential upside of 30.99%. Given Ortho Clinical Diagnostics' higher possible upside, analysts clearly believe Ortho Clinical Diagnostics is more favorable than Epigenomics.

Earnings & Valuation

This table compares Epigenomics and Ortho Clinical Diagnostics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EpigenomicsN/AN/AN/AN/AN/A
Ortho Clinical DiagnosticsN/AN/AN/AN/AN/A

Summary

Ortho Clinical Diagnostics beats Epigenomics on 2 of the 2 factors compared between the two stocks.

Epigenomics (OTCMKTS:EPGNY) and Biodesix (NASDAQ:BDSX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Valuation & Earnings

This table compares Epigenomics and Biodesix's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EpigenomicsN/AN/AN/AN/AN/A
BiodesixN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Epigenomics and Biodesix, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Epigenomics0000N/A
Biodesix00403.00

Biodesix has a consensus price target of $26.00, suggesting a potential upside of 34.23%. Given Biodesix's higher possible upside, analysts clearly believe Biodesix is more favorable than Epigenomics.

Profitability

This table compares Epigenomics and Biodesix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EpigenomicsN/AN/AN/A
BiodesixN/AN/AN/A

Summary

Biodesix beats Epigenomics on 2 of the 2 factors compared between the two stocks.

Epigenomics (OTCMKTS:EPGNY) and Lucira Health (NASDAQ:LHDX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Profitability

This table compares Epigenomics and Lucira Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EpigenomicsN/AN/AN/A
Lucira HealthN/AN/AN/A

Valuation & Earnings

This table compares Epigenomics and Lucira Health's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EpigenomicsN/AN/AN/AN/AN/A
Lucira HealthN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings for Epigenomics and Lucira Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Epigenomics0000N/A
Lucira Health10202.33

Lucira Health has a consensus price target of $9.00, indicating a potential upside of 14.80%. Given Lucira Health's higher probable upside, analysts clearly believe Lucira Health is more favorable than Epigenomics.

Summary

Lucira Health beats Epigenomics on 2 of the 2 factors compared between the two stocks.

Inotiv (NASDAQ:NOTV) and Epigenomics (OTCMKTS:EPGNY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Valuation and Earnings

This table compares Inotiv and Epigenomics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InotivN/AN/AN/AN/AN/A
EpigenomicsN/AN/AN/AN/AN/A

Profitability

This table compares Inotiv and Epigenomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InotivN/AN/AN/A
EpigenomicsN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings for Inotiv and Epigenomics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inotiv0000N/A
Epigenomics0000N/A

Epigenomics (OTCMKTS:EPGNY) and Akumin (NASDAQ:AKU) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Profitability

This table compares Epigenomics and Akumin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EpigenomicsN/AN/AN/A
AkuminN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Epigenomics and Akumin, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Epigenomics0000N/A
Akumin00103.00

Valuation & Earnings

This table compares Epigenomics and Akumin's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EpigenomicsN/AN/AN/AN/AN/A
AkuminN/AN/AN/AN/AN/A

Insider and Institutional Ownership

30.4% of Akumin shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Akumin beats Epigenomics on 2 of the 2 factors compared between the two stocks.


Epigenomics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
OLK
Olink Holding AB (publ)
0.0$37.50-1.1%$4.46 billionN/A0.00News Coverage
Ortho Clinical Diagnostics logo
OCDX
Ortho Clinical Diagnostics
1.8$18.53-1.7%$4.12 billionN/A0.00
Biodesix logo
BDSX
Biodesix
1.6$19.37-1.2%$514.82 millionN/A0.00News Coverage
Lucira Health logo
LHDX
Lucira Health
1.3$7.84-16.6%$302.11 millionN/A0.00Analyst Downgrade
Analyst Revision
NOTV
Inotiv
0.0$22.50-7.1%$250.45 millionN/A0.00Gap Down
Akumin logo
AKU
Akumin
0.6$3.07-0.0%$215.45 millionN/A0.00
Relay Medical logo
RYMDF
Relay Medical
0.0$0.39-11.5%$57.07 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
Global WholeHealth Partners logo
GWHP
Global WholeHealth Partners
0.0$0.69-2.9%$46.58 millionN/A0.00
ETAH
Eternity Healthcare
0.6$0.00-0.0%$0.00N/A0.00
MEDD
Medical Imaging
0.4$0.01-0.0%$0.00N/A0.00
Parallax Health Sciences logo
PRLX
Parallax Health Sciences
0.5$0.01-10.0%$0.00N/A0.00Gap Up
Siemens Healthineers logo
SMMNY
Siemens Healthineers
0.5$28.05-0.2%$0.00N/A0.00Decrease in Short Interest
WUXIF
WuXi AppTec
1.0$19.88-6.9%$0.00N/A0.00Gap Down
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.